Cargando…

Complications from Stereotactic Body Radiotherapy for Lung Cancer

Stereotactic body radiotherapy (SBRT) has become a standard treatment option for early stage, node negative non-small cell lung cancer (NSCLC) in patients who are either medically inoperable or refuse surgical resection. SBRT has high local control rates and a favorable toxicity profile relative to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kang, Kylie H., Okoye, Christian C., Patel, Ravi B., Siva, Shankar, Biswas, Tithi, Ellis, Rodney J., Yao, Min, Machtay, Mitchell, Lo, Simon S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2015
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4491695/ https://www.ncbi.nlm.nih.gov/pubmed/26083933 http://dx.doi.org/10.3390/cancers7020820

Ejemplares similares

Dose matters for stereotactic body radiotherapy for early stage non-small cell lung cancer
por: Okoye, Christian C., et al.
Publicado: (2020)

Stereotactic Body Radiotherapy for Primary Prostate Cancer
por: Kothari, Gargi, et al.
Publicado: (2018)

Focal Prostate Stereotactic Body Radiation Therapy With Correlative Pathological and Radiographic-Based Treatment Planning
por: Fredman, Elisha, et al.
Publicado: (2021)

Stereotactic Body Radiotherapy for Oligometastatic Disease in Non-small Cell Lung Cancer
por: Wujanto, Caryn, et al.
Publicado: (2019)

Comparative analysis for renal stereotactic body radiotherapy using Cyberknife, VMAT and proton therapy based treatment planning
por: Baydoun, Atallah, et al.
Publicado: (2018)

Using the Systemic Immune-Inflammation Index (SII) as a Mid-Treatment Marker for Survival among Patients with Stage-III Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
por: Biswas, Tithi, et al.
Publicado: (2020)

Evaluation of Definitive Stereotactic Body Radiotherapy and Outcomes in Adults With Extracranial Oligometastasis
por: Poon, Ian, et al.
Publicado: (2020)

Prognostic impact of biologically equivalent dose in stereotactic body radiotherapy for renal cancer
por: Tran, Kevin T., et al.
Publicado: (2023)

A Pilot Study Examining the Prognostic Utility of Tumor Shrinkage on Cone-Beam Computed Tomography (CBCT) for Stage III Locally Advanced Non-Small Cell Lung Cancer Patients Treated with Definitive Chemoradiation
por: Kang, Kylie H., et al.
Publicado: (2021)

Technical know‐how in stereotactic ablative radiotherapy (SABR)
por: Lo, Simon S., et al.
Publicado: (2016)

Curing Operable Stage I Non-Small Cell Lung Cancer With Stereotactic Ablative Body Radiotherapy: The Force Awakens
por: Siva, Shankar, et al.
Publicado: (2016)

Pretreatment neutrophil-to-lymphocyte ratio as an important prognostic marker in stage III locally advanced non-small cell lung cancer: confirmatory results from the PROCLAIM phase III clinical trial
por: Biswas, Tithi, et al.
Publicado: (2021)

Is there a role for stereotactic radiotherapy in the treatment of renal cell carcinoma?
por: Rühle, Alexander, et al.
Publicado: (2019)

Late metastatic presentation is associated with improved survival and delayed wide‐spread progression after ablative stereotactic body radiotherapy for oligometastasis
por: Chen, Xuguang, et al.
Publicado: (2021)

Risk for surgical complications after previous stereotactic body radiotherapy of the spine
por: Roesch, Johannes, et al.
Publicado: (2017)

Developments in Stereotactic Body Radiotherapy
por: Haridass, Anoop
Publicado: (2018)

Stereotactic ablative body radiotherapy (SABR) for bone only oligometastatic breast cancer: A prospective clinical trial
por: David, Steven, et al.
Publicado: (2019)

Stereotactic Body Radiotherapy for the Treatment of Renal Tumors()
por: Hanzly, Michael, et al.
Publicado: (2014)

Stereotactic body radiotherapy in the treatment of Pancreatic Adenocarcinoma in elderly patients
por: Kim, Carolyn H, et al.
Publicado: (2013)

Spine Stereotactic Body Radiotherapy: Indications, Outcomes, and Points of Caution
por: Tseng, Chia-Lin, et al.
Publicado: (2017)

Stereotactic Body Radiotherapy for Prostate Cancer
por: Parikh, Neil R., et al.
Publicado: (2020)

Multi-center evaluation of dose conformity in stereotactic body radiotherapy
por: Lee, Jonny, et al.
Publicado: (2019)

Stereotactic radiotherapy for oligoprogressive ER-positive breast cancer (AVATAR)
por: Alomran, Reem, et al.
Publicado: (2021)

Intratumoural renal cell carcinoma haemorrhage following stereotactic radiotherapy: a case report
por: Hilleary, Liam A., et al.
Publicado: (2019)

Stereotactic body radiotherapy for bone oligometastatic disease in prostate cancer
por: Patel, Priyanka H., et al.
Publicado: (2019)

Stereotactic ablative body radiotherapy versus conventionally fractionated radiotherapy for early stage large cell neuroendocrine carcinoma of the lung
por: Wegner, Rodney E, et al.
Publicado: (2020)

Current status of stereotactic body radiotherapy for the treatment of hepatocellular carcinoma
por: Park, Jongmoo, et al.
Publicado: (2019)

Stereotactic body radiotherapy for solitary spine metastasis
por: Lee, Sunyoung, et al.
Publicado: (2013)

A Survey of Stereotactic Body Radiotherapy in Korea
por: Bae, Sun Hyun, et al.
Publicado: (2015)

Stereotactic body radiotherapy in lung cancer: an update
por: Abreu, Carlos Eduardo Cintra Vita, et al.
Publicado: (2015)

Editorial: Stereotactic body radiotherapy for prostate cancer
por: Kishan, Amar U., et al.
Publicado: (2022)

Editorial: Stereotactic body radiotherapy for lung cancer
por: Liu, An, et al.
Publicado: (2023)

Stereotactic Body Radiotherapy Treatment for Recurrent, Previously Irradiated Head and Neck Cancer
por: Stanisce, Luke, et al.
Publicado: (2018)

Stereotactic Body Radiotherapy (SBRT) for Oligometastatic Spine Metastases: An Overview
por: Zeng, Kang Liang, et al.
Publicado: (2019)

Stereotactic Body Radiotherapy (SBRT) for Oligometastatic Lung Nodules: A Single Institution Series
por: Wegner, Rodney E., et al.
Publicado: (2019)

Stereotactic body radiotherapy for recurrent and oligometastatic soft tissue sarcoma
por: Feng, Xiao-Yao, et al.
Publicado: (2022)

Institutional analysis of stereotactic body radiotherapy (SBRT) for oligometastatic lymph node metastases
por: Yeung, Rosanna, et al.
Publicado: (2017)

The Judicious Use of Stereotactic Ablative Radiotherapy in the Primary Management of Localized Renal Cell Carcinoma
por: Barbour, Andrew B., et al.
Publicado: (2023)

Diffusion weighted and dynamic contrast enhanced MRI as an imaging biomarker for stereotactic ablative body radiotherapy (SABR) of primary renal cell carcinoma
por: Reynolds, Hayley M., et al.
Publicado: (2018)

Efficacy of Stereotactic Body Radiotherapy in Patients With Hepatocellular Carcinoma Not Suitable for Transarterial Chemoembolization (HERACLES: HEpatocellular Carcinoma Stereotactic RAdiotherapy CLinical Efficacy Study)
por: Brunner, Thomas B., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_lbhrpavvo0neuggd18eg4r4doi